Bristol Myers Squibb Company
430 E. 29th St
About Bristol Myers Squibb Company
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
At Bristol Myers Squibb, we believe in the power of science to address some of the most challenging diseases of our time. Our focus on these unmet needs comes during a remarkable time, when unprecedented scientific breakthroughs are advancing the treatment of disease as never before in human history.
We work every day to transform patients’ lives through science. Each day, our employees around the world work together for patients – they are at the center of everything we do. They inspire us. They are the reason we come to work each day.
We combine the agility of a biotech with the reach and resources of an established pharmaceutical company to create a global leading biopharma company powered by talented individuals who drive scientific innovation.
Possibility Lives at BMS!
2677 articles with Bristol Myers Squibb Company
PicnicHealth Announces Engagement with Bristol Myers Squibb to Leverage Real-World Evidence to Study Symptomatic Obstructive Hypertrophic Cardiomyopathy Patients
PicnicHealth, a patient-centered health technology company, today announced an engagement with Bristol Myers Squibb to leverage patient-centered, real-world evidence generation to complement Bristol Myers Squibb’s DISCOVER-HCM Registry, a 1,500-patient registry of consented symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients receiving CAMZYOS (mavacamten) or other treatment.
Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million
Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced a $25 million equity investment from Bristol Myers Squibb and a term loan facility with access to up to $125 million from Hercules Capital, Inc.
Data Reinforcing Impact of Bristol Myers Squibb Cardiovascular Portfolio to be Presented at American Heart Association Scientific Sessions 2022
Bristol Myers Squibb announced the presentation of research demonstrating the strength of the company’s cardiovascular franchise at the American Heart Association’s annual Scientific Sessions, taking place in-person and virtually November 5-7, 2022.
Merck, Bristol Myers Squibb, Biogen and others presented their latest data from MS programs at the 38th ECTRIMS conference.
Bristol Myers Squibb (NYSE:BMY) today reports results for the third quarter of 2022, which reflect strong in-line and new product portfolio growth.
New Zeposia (ozanimod) Data Highlight COVID-19 Outcomes and Preservation of Long-Term Cognitive Function from Separate Analyses in Patients with Relapsing Forms of Multiple Sclerosis
Bristol Myers Squibb announced new retrospective analyses on serologic responses and clinical outcomes with COVID-19 vaccination in participants treated with Zeposia from the ongoing Phase 3 DAYBREAK open-label extension study in relapsing multiple sclerosis.
New Data Presented at the American College of Gastroenterology Annual Scientific Meeting Demonstrate Continuous Zeposia (ozanimod) Treatment Prevents Disease Relapse Over One Year
New Data Presented at the American College of Gastroenterology Annual Scientific Meeting Demonstrate Continuous Zeposia (ozanimod) Treatment Prevents Disease Relapse Over One Year in 86.1% of Patients Who Respond at the End of the Induction Period.
BMS's blockbuster checkpoint inhibitor Opdivo hit the primary endpoint in the Phase III CheckMate -76K trial for a particularly intractable form of melanoma.
Bristol Myers Squibb Presents Data from CheckMate -76K Showing Opdivo (nivolumab) Reduced the Risk of Recurrence or Death by 58% Versus Placebo in Patients with Completely Resected Stage IIB or IIC Melanoma
Bristol Myers Squibb announced results from the Phase 3 CheckMate -76K trial, in which Opdivo as an adjuvant therapy demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival versus placebo in patients with completely resected stage IIB or IIC melanoma.
10/19/2022The Biotech Bay region is home to 3,418 life sciences companies and 96,574 employees making an average of $148,285. Here's a look at a few of the bay area biotech companies hiring now.
Bristol Myers Squibb Announces Change to Earnings Conference Call Dial-In Information for Third Quarter 2022 Results Scheduled for October 26, 2022
Bristol Myers Squibb (NYSE:BMY) announced that it has changed the dial-in and replay information of its previously announced third quarter 2022 earnings conference call scheduled for Wednesday, October 26, 2022.
Bristol Myers Squibb entered two separate research collaboration and licensing deals, one with San Francisco-based SyntheX and the second with London’s Autolus Therapeutics.
SyntheX and Bristol Myers Squibb Enter Into a Research Collaboration to Discover and Develop Targeted Protein Degradation (TPD) Therapeutics
SyntheX, Inc., an emerging growth biotechnology company innovating next-generation functional drug discovery engines, announced a research collaboration and license agreement with Bristol Myers Squibb to discover, develop and commercialize novel small molecules using SyntheX's ToRNeDO platform for protein degradation.
Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STELLAR-002 Trial
Exelixis, Inc. announced the expansion of its June 2021 Clinical Trial Collaboration and Supply Agreement with Bristol-Myers Squibb Company to include the use of the fixed-dose combination of nivolumab and relatlimab in the ongoing phase 1b STELLAR-002 clinical trial, which is evaluating XL092 in combination with multiple immune checkpoint inhibitors in advanced solid tumors.
Both Bristol Myers Squibb and AbbVie filed a WARN notice with the California state government stating they intend to lay off up to 360 people.
Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab), for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression
Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved the fixed-dose combination of Opdualag (nivolumab and relatlimab) for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumor cell PD-L1 expression < 1%.
Bristol Myers Squibb Announces Adjuvant Treatment with Opdivo (nivolumab) Demonstrated Statistically Significant and Clinically Meaningful Improvement in Recurrence-Free Survival (RFS)
Bristol Myers Squibb Announces Adjuvant Treatment with Opdivo (nivolumab) Demonstrated Statistically Significant and Clinically Meaningful Improvement in Recurrence-Free Survival (RFS) in Patients with Stage IIB/C Melanoma in the CheckMate -76K Trial.
There's a new collaboration in the Parkinson's disease development space, Cardiff Oncology kicks off a mid-phase study in colorectal cancer and Ocugen published a new review of COVAXIN.
Bristol Myers Squibb announced that its Board of Directors has declared a quarterly dividend of fifty-four cents per share on the $.10 par value common stock of the company.
BMS validated LAG-3 as the newest checkpoint in immuno-oncology in March. Regeneron, Merck and Immutep S.A. have been working hard to develop the next successful LAG-3 inhibitor.